Brief: Neovacs announces FDA acceptance of new IND to expand Ifnalpha Kinoid clinical development program in dermatomyositis

Neovacs SA

19/07/2017 06:30

July 19 (Reuters) - NEOVACS SA  ALNEV.PA : 
    * REG-NEOVACS ANNOUNCES FDA ACCEPTANCE OF A NEW IND TO 
EXPAND IN U.S. IFNALPHA KINOID CLINICAL DEVELOPMENT PROGRAM IN 
DERMATOMYOSITIS 
    * CAN NOW INITIATE IN THE US ITS PHASE IIA CLINICAL TRIAL 
ALREADY ON-GOING IN EUROPEAN COUNTRIES 
    * PHASE IIA CLINICAL TRIAL CURRENTLY BEING CONDUCTED IN 
EUROPE (FRANCE, ITALY, GERMANY, AND SWITZERLAND) IN 30 ADULT 
PATIENTS 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nGNE3KrN34 
Further company coverage:  ALNEV.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))